News | August 11, 2021
Sequent Scientific net profit at Rs 87.30 lakh in Q1FY22
Formulation business grew by 15 per cent in the quarter
Formulation business grew by 15 per cent in the quarter
This robust performance is a testimony of the company's agility, resilience and strong execution capabilities during these difficult times
A globally approved pen filled by mass technology provides a safer self- administration fertility solution
A veteran in cell therapy and oncology commercialisation
Phase II trial will evaluate the safety and efficacy of ASC40 in patients with moderate to severe acne
Board declares interim dividend of Rs 2 per equity share
All India Institute of Ayurveda hosts ministers and showcase their achievements
The company expects revenue growth of 10-15 per cent in the US
The transaction is expected to close in the Q4FY22
Advances deployment of mRNA technology across vaccines and therapeutics development
Subscribe To Our Newsletter & Stay Updated
